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aims/hypothesis: Existing studies suggest that decreased branched-chain amino 
acid (BCAA) catabolism and thus elevated levels in blood are associated with metabolic 
disturbances. Based on such information, we have developed a hypothesis how BCAA 
degradation mechanistically connects to tricarboxylic acid cycle, intramyocellular lipid 
storage, and oxidation, thus allowing more efficient mitochondrial energy production 
from lipids as well as providing better metabolic health. We analyzed whether data from 
aged Finnish men are in line with our mechanistic hypothesis linking BCAA catabolism 
and metabolic disturbances.
Methods: Older Finnish men enriched with individuals having been athletes in young 
adulthood (n =  593; mean age 72.6 ±  5.9  years) responded to questionnaires, par-
ticipated in a clinical examination including assessment of body composition with bio-
impedance and gave fasting blood samples for various analytes as well as participated 
in a 2-h 75  g oral glucose tolerance test. Metabolomics measurements from serum 
included BCAAs (isoleucine, leucine, and valine).
results: Out of the 593 participants, 59 had previously known type 2 diabetes, further 67 
had screen-detected type 2 diabetes, 127 impaired glucose tolerance, and 125 impaired 
fasting glucose, while 214 had normal glucose regulation and one had missing glucose 
tolerance information. There were group differences in all of the BCAA concentrations 
(p ≤ 0.005 for all BCAAs), such that those with normal glucose tolerance had the low-
est and those with diabetes mellitus had the highest BCAA concentrations. All BCAA 
levels correlated positively with body fat percentage (r = 0.29–0.34, p < 0.0001 for all). 
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inTrODUcTiOn
High serum branched-chain amino acid (BCAA; isoleucine, 
leucine, and valine) concentrations have been shown to be pre-
dictors or markers of insulin resistance (1), obesity (2, 3), diabetes 
(4, 5), and atherogenetic dyslipidemia (6, 7) and response to a 
test meal (8). A 12-year prospective follow-up study of initially 
normoglycemic individuals showed an association between high 
serum BCAA levels and incidence of type 2 diabetes (4). In our 
studies, the metabolomics of twin pairs discordant for leisure-
time physical activity for 30 years revealed lower concentrations 
of serum BCAAs, especially isoleucine, in the active vs. inactive 
co-twin (9). Serum isoleucine was confirmed to be low in physi-
cally active persons in three different population-based cohorts 
(9). Similarly, the transcriptomics of skeletal muscle and adipose 
tissue yielded upregulated mRNA expression signature of BCAA 
catabolism and fatty acid metabolism in active compared to inac-
tive co-twins (10). Animal studies support the findings in humans 
(11, 12). BCAAs are oxidized and used for energy production 
during exercise. Interestingly, the prevention of the first step of 
BCAA catabolism by deleting the Bcat2 gene encoding BCAA 
aminotransferase, the first enzyme in BCAA catabolism, renders 
mice exercise intolerant, affirming that BCAA catabolism is 
necessary for exercise performance (13). Skeletal muscle has the 
highest capacity not only to catabolize BCAAs in humans but also 
adipose tissue, brain, and liver play important roles (14).
In sum, the existing metabolomic and transcriptomic stud-
ies suggest that decreased BCAA catabolism, and thus elevated 
levels in blood are associated with low physical activity, increased 
adiposity, and other risk factors for metabolic diseases. We have 
developed a mechanistic hypothesis (BCAA–FatOx hypothesis) 
that intertwines BCAA catabolism with the tricarboxylic acid 
(TCA) cycle and lipid metabolism allowing better lipid oxida-
tion and better metabolic health (Figure 1) (15), thus completely 
explaining the mechanistic background of these associations. The 
aim of the current study was to test whether data from elderly 
Finnish men are in line with this mechanistic hypothesis. In 
more detail, we tested whether indicators of impaired oxida-
tive fat metabolism selected on the basis of earlier reports (9, 
15–21) (impaired glucose regulation, high body fat percentage, 
impaired liver metabolism, low leisure-time physical activity, 
and accumulation of indicators of low fat oxidation in lipopro-
tein sub-fractions) are associated with increased serum BCAA 
concentrations.
MaTerials anD MeThODs
Participants and study Design
The participants were members of the cohort of male former 
Finnish elite athletes and their controls (22, 23), which means that 
the cohort was enriched with individuals having a documented 
history of an extended period of high physical activity level. The 
original cohort (n = 4136) consisted of male former elite athletes 
who represented Finland between the years 1920 and 1965 at least 
once in international competitions (Olympic Games, World or 
European Championships, or other intercountry competitions) 
and their age- and area-matched controls. The controls were clas-
sified as healthy at the medical examination, which all Finnish 
men undergo at age 20  years as part of the national military 
service. By the year 2008, 2702 (65.3%) of the cohort members 
had died.
Of the surviving cohort members, 1183 were invited to a 
clinical study in 2008 (24). The invitation was sent to all surviving 
cohort members who had responded at least once to the previ-
ous questionnaires sent in 1985, 1995, or 2001. Of those invited, 
599 participated in the physical examination and completed the 
questionnaires. Of the participants, 594 provided fasting blood 
samples. One of these had type 1 diabetes and was excluded 
from the study, thus 593 comprised the target group of this paper 
(Table 1).
The ethics committee of the Hospital District of Helsinki and 
Uusimaa approved the study, and all subjects have provided writ-
ten informed consent.
Measurements and Definitions
Trained study nurses performed the physical examinations 
including assessment of body weight, height, body composi-
tion, and blood sampling in field survey laboratories around 
Finland.
Body composition was determined in light indoor clothing 
and without shoes and socks by a bioimpedance body composi-
tion device (InBody 3.0, Biospace, Seoul, South Korea): fat-free 
mass (FFM) to an accuracy of 0.1 kg and fat mass to an accuracy 
of 0.1 kg. Fat percent was calculated as fat mass divided by body 
weight and converted to percent. The body composition device 
measured body weight to an accuracy of 0.1 kg. If the participant 
had a pacemaker causing an exclusion from bioimpedance body 
composition analysis (n = 14), weight was measured by a digital 
Expected associations with high BCAA concentrations and unfavorable metabolic profile 
indicators from metabolomics analysis were found. Except for glucose concentrations, 
the associations were stronger with isoleucine and leucine than with valine.
conclusion/interpretation: The findings provided further support for our hypothesis 
by strengthening the idea that the efficiency of BCAA catabolism may be mechanistically 
involved in the regulation of fat oxidation, thus affecting the levels of metabolic disease 
risk factors.
Keywords: branched-chain amino acids, metabolic disease, tricarboxylic acid cycle, lipid oxidation, mitochondria, 
energy metabolism
FigUre 1 | hypothesized interplay between skeletal muscle Bcaa catabolism and fatty acid metabolism. We recently proposed how BCAA degradation 
mechanistically connects to lipid storage and oxidation in skeletal muscle (15). (a) In mitochondria, the first reaction of the BCAA catabolism is the transfer of amino 
group from BCAA to a tricarboxylic acid (TCA) cycle intermediate α-ketoglutarate (α-KG) to form glutamate (Glu) in a reaction catalyzed by mitochondrial 
branched-chain aminotransferase (BCATm). Deaminated BCAAs are further decarboxylated and processed to supply acetyl-CoA and succinyl-CoA for the TCA 
cycle. (B) In this model, cytosolic oxaloacetate is further metabolized to phosphoenolpyruvate for glyceroneogenesis, which is required in skeletal muscles for the 
storage of fatty acids in lipid droplets (LDs). Similarly, β-oxidation of fatty acids provides acetyl-CoA and also succinyl-CoA. It is worth noting that during moderate-
intensity exercise acetyl-CoA supply from pyruvate is inhibited by PDK4-catalyzed phosphorylation of the pyruvate dehydrogenase complex, thus favoring 
β-oxidation. During exercise, the muscle concentration of α-ketoglutarate decreases and the concentrations of the other TCA metabolites increase, the 
concentration of malate being the highest. In the presented model, cytosolic malate, which is required for the functioning of the malate–aspartate shuttle, is 
transported from the mitochondria to cytosol via the dicarboxylate carrier. Both TCA cycle and β-oxidation provide NADH and/or NADPH to electron transport 
chain for cellular energy production (ATP/heat). Shortly, we suggested that during increased demand for BCAA catabolism, e.g., during exercise due to increased 
energy-yielding substrate requirement, transamination of BCAAs is essential for cytosolic oxaloacetate formation. Ala, alanine; α-KIC, α-ketoisocaproate;  
α-KIV, α-ketoisovalerate; α-KMV, α-keto-β-methylvalerate; BCKD, branched-chain α-ketoacid dehydrogenase; BCKD kinase, branched-chain α-ketoacid 
dehydrogenase kinase; ETC, electron transport chain; FFA, free fatty acid; GA3P, glyceraldehyde-3-phosphate; Ile, isoleucine; Leu, leucine; OAA, oxaloacetate; 
PDK4, pyruvate dehydrogenase kinase-4; PEP, phosphoenolpyruvate; PEPCK-C, cytosolic phosphoenolpyruvate carboxykinase; PP2Cm, BCKD phosphatase;  
Val, valine. Reproduced by the permission provided by Wolters Kluwer Health, Inc. from the article: Kainulainen et al. (15).
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scale with the same accuracy. Height was measured without 
shoes on with a measuring tape against the wall to an accuracy 
of 0.1 cm. Body mass index (BMI) was calculated as body weight 
divided by the square of the body height (kilograms per square 
meter).
Venous blood samples were taken after 10 h fasting in a sit-
ting position with a light stasis into a serum gel tube (Venosafe, 
Terumo Europe) for metabolomics, lipid, and liver enzyme 
assays into a serum tube (Venosafe) for insulin assay and into 
a fluoride–citrate tube (Venosafe) for glucose assay. The venous 
blood samples were centrifuged at the field survey sites. The 
plasma and sera were frozen immediately after separating 
and transferred in dry ice to the laboratory once a week for 
analyses. Lipids, alanine aminotransferase (Alat), aspartate ami-
notransferase (AST), γ-glutamyl transferase (Gt), insulin, and 
glucose measurements were performed on a clinical chemistry 
analyzer Architect ci8200 (Abbott Laboratories, Abbott Park, 
IL, USA) at the laboratory of National Institute for Health and 
Welfare (Helsinki, Finland). The following methods were used: 
enzymatic assay (Abbott Laboratories) for measuring serum 
total cholesterol, homogenous assay (Abbott Laboratories) for 
direct measurement of serum high density lipoprotein (HDL) 
cholesterol, enzymatic glycerol phosphate oxidase assay (Abbott 
Laboratories) for measuring serum triglycerides, International 
Federation of Clinical Chemistry (IFCC) method (Abbott 
Laboratories) for measuring ALT and AST, kinetic method 
(Abbott Laboratories) for measuring GT, chemiluminescent 
microparticle immunoassay (CMIA, Abbott Laboratories) for 
measuring insulin and enzymatic hexokinase assay (Abbott 
Laboratories) for plasma glucose. Low density lipoprotein (LDL) 
cholesterol was calculated by the Friedewald formula (25). For 
standardizing measurements, the laboratory has taken part in 
Lipid Standardization Program organized by CDC (Atlanta, GA, 
USA) and External Quality Assessment Schemes organized by 
Labquality (Helsinki, Finland). During the course of the study, the 
coefficient of variation of control samples (CV) (mean ± SD) was 
0.9% ± 0.2 for total cholesterol, 1.9% ± 0.5 for HDL-cholesterol, 
1.9% ± 0.5 for triglycerides, 4.9% ± 5.0 for ALT, 1.6% ± 1.0 for 
AST, 1.6% ± 0.4 for GT, 1.9% ± 0.4 for insulin, and 1.8% ± 0.3 
for glucose.
TaBle 1 | Participant characteristics according to glucose tolerance.
normal (n = 214) igT or iFg (n = 252) T2D or sT2D (n = 126) p-Value†
Mean ± sD
Age (years) 71.6 ± 6.1 72.7 ± 5.9 72.9 ± 5.7 0.065
Height (cm) 176 ± 7 175 ± 8* 174 ± 8** 0.010
Weight (kg) 79.7 ± 10.8 81.6 ± 13.2 85.7 ± 16.6** 0.004
Body mass index (kg/m2) 25.6 ± 2.7 26.6 ± 3.5** 28.2 ± 4.7*** <0.001
Body fat (%) 23.7 ± 4.9 25.3 ± 5.7** 27.4 ± 6.4*** <0.001
Leisure-time physical activity volume (MET-h/week) 32.3 ± 29.7 28.3 ± 26.6* 18.8 ± 19.3*** <0.001
Alanine aminotransferase (U/L) 23.7 ± 9.9 26.1 ± 11.2* 30.7 ± 21.0** 0.013
γ-glutamyltransferase (U/L) 32.1 ± 19.4 36.5 ± 30.8 53.1 ± 56.2*** <0.001
Glucose (mmol/L) 4.31 ± 0.24 4.76 ± 0.32*** 5.60 ± 1.42*** <0.001
Serum total triglycerides (mmol/L) 1.03 ± 0.33 1.09 ± 0.39 1.17 ± 0.59 0.064
Total fatty acids (mmol/L) 9.91 ± 1.59 9.92 ± 1.81 10.03 ± 2.50 0.934
Total lipids in chylomicrons and extremely large VLDL (μmol/L) 17 ± 13 19 ± 15 23 ± 34 0.168
Total lipids in very large VLDL (μmol/L) 38 ± 36 45 ± 40* 55 ± 74* 0.029
Total lipids in large VLDL (μmol/L) 162 ± 123 183 ± 141 214 ± 212 0.065
Mean diameter for VLDL particles (nm) 35.96 ± 1.10 36.13 ± 1.11 36.32 ± 1.30** 0.017
Mean diameter for HDL particles (nm) 9.97 ± 0.24 9.94 ± 0.25 9.90 ± 0.24** 0.007
Ratio of apolipoprotein B to apolipoprotein A-I 0.565 ± 0.109 0.566 ± 0.118 0.557 ± 0.130 0.645
Glycoprotein acetyls, mainly α1-acid glycoprotein (mmol/L) 1.39 ± 0.15 1.43 ± 0.16** 1.48 ± 0.20*** <0.001
Isoleucine (μmol/L) 53 ± 10 55 ± 11 59 ± 15*** 0.001
Leucine (μmol/L) 78 ± 12 80 ± 14 87 ± 22*** <0.001
Valine (μmol/L) 179 ± 29 185 ± 29* 196 ± 45*** <0.001
Data are mean ± SD.
†p for group differences by Kruskal–Wallis test.
Statistical difference compared to normal glucose group using Dunn procedure; *p < 0.05; **p < 0.01; ***p < 0.001.
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Participating men without a history of diabetes had a standard 
2 h 75 g OGTT. A blood sample was drawn 2 h after the inges-
tion of the 300 mL solution, containing 75 g anhydrous glucose 
and 0.8 g citric acid. In this study, a definition of type 2 diabetes 
impaired fasting glucose (IFG) and impaired glucose tolerance 
(IGT) was done according to WHO criteria from year 1999 (26). 
If the participant had both IFG and IGT, he was defined to have 
IGT. One participant was unclassified due to missing data from 
the OGTT.
Metabolic syndrome was defined according to criteria of the 
International Diabetes Federation: waist circumference >94 cm 
plus any two of the following factors: (i) TG >1.7  mmol/L or 
specific treatment for this, (ii) HDL <1.03  mmol/L or specific 
treatment for this, (iii) systolic BP ≥130 or diastolic BP ≥85 mm 
Hg or treatment of previously diagnosed hypertension, (iv) fast-
ing plasma glucose ≥5.6 mmol/L or previously diagnosed type 
2 diabetes (27). Lipid values measured at laboratory in National 
Institute for Health and Welfare were used for metabolic syn-
drome determination.
Metabolomics analysis
Serum samples were kept at −80°C until analyzed with a NMR 
metabolomics platform, which provides quantitative information 
on lipoprotein subclass lipid distribution and particle concentra-
tions, serum lipids including fatty acids, and low-molecular-
weight metabolites such as amino acids (9, 16, 28). Updated 
information on the current version of the metabolomics platform 
used is described at http://computationalmedicine.fi/platform. 
From these data, selected metabolic measures (Table 1) reflecting 
disturbed oxidative lipid metabolism together with the BCAA’s 
were included in the present analysis. Specific lipid values from 
metabolomics platform were used to study their associations with 
BCAA levels.
statistical analysis
Data have been reported as means ±  SD. Group differences in 
BCAA levels were tested using Mann–Whitney U-test or Kruskal–
Wallis test with post  hoc comparisons using Dunn procedure. 
Spearman correlations with 95% confidence intervals between 
BCAAs and other serum indicators of disturbed oxidative lipid 
metabolism were calculated with bootstrapping (1000 samples). 
Further, age-, physical activity-, and body fat percentage-adjusted 
correlations were calculated utilizing the partial correlation pro-
cedure with bootstrapping. All analyses were carried out using the 
IBM SPSS version 21.0 (IBM Ltd., Armonk, NY, USA). p Values 
<0.05 were considered statistically significant. As we studied the 
association between disturbed metabolism and BCAA values, as 
age adjustment influenced our results only minimally and as in 
our material the former endurance athletes were older than other 
participants and they are known to have better metabolic health 
than other participants (24) we give our results on our aged study 
group without age-adjustment. Graphical network analysis of 
metabolomics variables, physical activity measures (MET), body 
fat%, and liver function parameters Alat and Gt was conducted 
with the Katiska software (http://www.finndiane.fi/software/
katiska/) (29).
FigUre 2 | Branched-chain amino acid concentrations (mean and 95% confidence intervals) in different diabetes/glucose level groups. p values 
indicate difference from normal glucose group according to post hoc Dunn procedure. IFG, impaired fasting glucose; IGT, impaired glucose tolerance; ST2D, 
screen-detected type 2 diabetes; T2D, known type 2 diabetes.
TaBle 2 | Bcaa values according to presence of metabolic syndrome.
Occurrence of metabolic syndrome
Yes (n = 323) no (n = 265) p-Value*
Mean (95% ci)
Isoleucine, μmol/L  58 (57–60)  51 (50–53) <0.001
Leucine, μmol/L  85 (83–86)  77 (75–79) <0.001
Valine, μmol/L 191 (188–195) 178 (175–182) <0.001
*p Values are for difference between those with and without metabolic syndrome by 
Mann–Whitney U-test.
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resUlTs
Out of the 593 participants, 59 had previously known type 2 dia-
betes, further 67 had screen-detected type 2 diabetes (ST2D), 127 
IGT, and 125 IFG, while 214 had normal fasting glucose concen-
tration and normal glucose tolerance (data missing for OGTT for 
one participant). Expectedly, the isoleucine, leucine, and valine 
concentration correlated highly with each other (r ≥ 0.66 for all 
correlations). There were statistically significant group differences 
in all of the BCAA concentrations (p ≤ 0.005 for all BCAAs) the 
participants with normal glucose regulation having lowest and 
those with type 2 diabetes the highest BCAA concentrations. 
BCAA concentrations with post  hoc statistical comparisons 
according to diabetes/glucose level groups are shown in Figure 2.
According to the International Diabetes Federation criteria, 
323 participants had metabolic syndrome. Those participants with 
metabolic syndrome had higher BCAA concentrations compared 
to those without (p < 0.001 for each of the BCAAs, Table 2) (data 
missing for 5). All BCAA concentrations correlated positively 
with body fat percentage (r = 0.29–0.34, p < 0.0001 for all). Also, 
all BCAA concentrations correlated with alanine aminotrans-
ferase and γ-glutamyltransferase concentration, p ≤  0.0002 for 
all correlations (Figure  3). In addition, statistically significant 
negative correlations between recent leisure-time physical activity 
(MET-h/week) and isoleucine, leucine, and valine were observed. 
Associations with fasting glucose and the selected indicators of 
disturbed oxidative lipid metabolism/cardiometabolic risk from 
metabolomics are also shown in Figure 3. When adjusted with 
age, physical activity (MET-h/week) and body fat percentage 
these correlations remained at the same level (only for valine 
some correlations were attenuated). These correlations with 95% 
confidence intervals are presented in Table S1 in Supplementary 
Material. Expected associations with high BCAA concentra-
tions and unfavorable metabolic profile indicators were found. 
Interestingly, the associations were stronger with isoleucine 
and leucine than with valine except for fasting glucose showing 
similar level of associations. Stronger association of isoleucine 
FigUre 3 | correlation data of Bcaas. (a–c) Spearman correlations of isoleucine, leucine, and valine with other variables associated with oxidative lipid 
metabolism. Orange and blue lines indicate positive and negative correlations, respectively. p Values for all BCAAs in comparisons with body fat% were <0.0001. 
For physical activity (MET-h/week), the significance values were p = 0.003 (isoleucine), p = 0.008 (leucine), and p = 0.016 (valine). Correlations between all BCAAs 
and liver function analytes (Alat, γ-Gt) were highly significant (p < 0.0001 except between valine and γ-Gt p = 0.0002). Correlations between BCAAs and other 
selected indicators of cardiometabolic risk from metabolomics platform were highly significant (p < 0.0001) except between valine and tot TG (p = 0.28), XXL VLDL 
(p = 0.002), and ApoB/ApoA1 (p = 0.022). (D) Data-driven association network of serum BCAA concentrations and other factors related to oxidative lipid 
metabolism. Alat indicates alanine aminotransferase; Apo, apolipoprotein; Gp, α1-acid glycoprotein; Gt, γ-glutamyltransferase; HDL, high-density lipoprotein;  
L VLDL, XL VLDL, and XXL VLDL, large, very large, and extremely large very-low-density lipoprotein, respectively; s-Glc, serum glucose; s-TG, serum triglycerides; 
tot FA, total fatty acids. In (a–c), red line denotes positive and blue line negative correlation; in (D), red line denotes positive and blue line negative association, and 
more intensive color denotes higher association.
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and leucine with serum triglycerides than that of valine was also 
seen (Figure 4).
DiscUssiOn
Our study is consistent with and extends the evidence for the 
hypothesis that BCAA catabolism and oxidative energy metabo-
lism and metabolic disturbances are intertwined via the use of 
BCAAs in TCA cycle.
strengths and limitations
In this study, we did not have diary-based food records to study 
how BCAA intake influences serum BCAA concentrations. 
Instead, we had food frequency questionnaire (30) based calcula-
tions of different BCAA intakes. These intakes did not correlate 
with fasting serum BCAA concentrations, which is in line with 
the idea that our findings were not due to variations in dietary 
intake of the studied BCAAs (9). Some of the blood lipids were 
analyzed both using standard clinical chemistry methods and the 
metabolomics platform. These measurements correlated highly 
and using values from these differing measurement techniques 
gave very similar results.
The use of BIA to measure body composition may be regarded 
as a limitation. BIA was used in order to provide comparable 
results between the study centers, since all centers did not have a 
possibility to use dual-energy x-ray absorptiometry (DEXA) that 
is considered one of the main methods to measure body composi-
tion. Another limitation is the cross-sectional nature of the study 
setup that does not allow causal interpretation. Furthermore, 
only males were included to the study so the results cannot be 
extrapolated to women.
comparison with Other studies
Our results agree with earlier data showing that in rodents and 
humans with impaired glucose regulation, increased BCAA con-
centrations have been reported (4, 31, 32). These findings are in 
FigUre 4 | scatter plots depicting the associations of serum (a) 
isoleucine, (B) leucine, and (c) valine with serum trigyceride 
concentration. The person with the highest triglyceride concentration is a 
patient with insulin treatment for type 2 diabetes.
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line with our hypothesis that serum BCAAs are elevated when the 
catabolism of BCAAs to be used in oxidative energy metabolism 
in TCA cycle is disturbed. Also, in agreement with previous data, 
BCAA concentrations were higher among participants with 
metabolic syndrome compared to those without. Expectedly, 
high body fat percent that is a characteristic for individuals with 
metabolic syndrome associated with elevated BCAA concentra-
tions. The BCAA concentrations are increased in particular 
among obese individuals with metabolic syndrome (21). The 
findings on the association between recent high physical activity 
level and reduced levels of BCAAs are in agreement with recent 
data (9). Of the commonly used serum analytes reflecting liver 
function, serum alkaline phosphatase, and γ-glutamyltransferase 
have been shown to be most strongly related to the occurrence 
of non-alcoholic fatty liver disease NAFLD (20). Serum BCAA 
concentrations associated with these analytes. In metabolic syn-
drome, there is an accumulation of large VLDL and postprandial 
remnants lipoproteins, which are known to have high atherogenic 
potential (18), while large HDL particles are less atherogenic than 
small HDL particles (9, 16, 19). On the basis of this knowledge, 
we selected from the metabolomics platform a set of variables 
typically indicating atherogenic metabolic profile related to insuf-
ficient oxidative lipid metabolism, and found strong associations 
with serum BCAA concentrations, in particular with isoleucine 
and leucine.
The findings are in line with our BCAA–FatOx hypothesis 
(15), although they do not give final proof on the hypothesized 
mechanism. The BCAA–FatOx hypothesis (see Figure  1 for 
more details) proposes how BCAA degradation is mechanisti-
cally connected to lipid storage and oxidation in skeletal muscle 
(15). Shortly, the first reaction of the BCAA catabolism in 
mitochondria is the transfer of amino group from BCAA to a 
TCA cycle intermediate α-ketoglutarate to form glutamate by the 
mitochondrial branched-chain aminotransferase. Glutamate and 
mitochondrial oxaloacetate form aspartate that is transferred via 
malate–aspartate shuttle to cytosol. In our model, cytosolic aspar-
tate is processed to oxaloacetate that is further metabolized to 
phosphoenolpyruvate for glyceroneogenesis. Glyceroneogenesis 
is required in skeletal muscles for the storage of fatty acids in 
intramyocellular lipid droplets. Similar to BCAA catabolism, 
β-oxidation of fatty acids from lipid droplets provides acetyl-CoA 
and also succinyl-CoA. Briefly, we suggest that BCAA catabolism 
is essential for cytosolic oxaloacetate formation and thereafter for 
storing fatty acids as lipid droplets. Accordingly, as in the present 
study, disturbed lipid metabolism can be seen as higher serum 
concentrations of BCAAs.
Interestingly, the associations of indicators of disturbed 
oxidative fat metabolism with valine were weaker than 
with isoleucine and leucine (see Table S1 in Supplementary 
Material). This may be due to the fact that valine is catabolized 
to succinyl-CoA, while degradation of isoleucine and leucine 
provides acetyl-CoA to the TCA cycle, which may be a more 
rate-limiting step.
Unanswered Questions and Future 
research
We also calculated correlations with the indicators of impaired 
lipid metabolism and other serum amino-acid concentrations 
measured using the metabolomics platform (alanine, glutamine, 
glycine, histidine, phenylalanine, and tyrosine), but only three 
correlations showed a moderate correlation (r > 0.3) with pheny-
lalanine (results not shown). It is to note that BCAA and aromatic 
amino acid metabolism may have other multiple associations 
with different metabolites (33), but the analyses we presented 
only focused on the mechanistic key link between the catabolism 
of BCAAs and lipid metabolism.
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Of the BCAAs leucine and its catabolites, α-ketoisocaproic 
acid and β-hydroxy-β-methylbutyrate are known activators of 
mTOR pathway, thus regulating muscle protein synthesis (34). 
Also, the intermediate product of valine catabolism, 3-hydroxy-
isobutyrate, has been shown to be secreted out of muscle cells 
and to activate in a paracrine manner transendothelial fatty acid 
transport and to promote muscle fatty acid uptake (35). The 
supplementation of the third BCAA, isoleucine, has been found 
to increase the expression of the proton uncoupler UCP3 and 
the molecular markers of lipid mobilization as well as to reduce 
body and adipose tissue weight gain during a high-fat diet (36). It 
remains to be shown what is the actual mechanism of isoleucine 
in concert with other BCAAs in the suggested regulation of basal 
metabolic rate.
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